LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

3.11 -2.2

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.11

Максимум

3.35

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+521.12% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-73M 316M
Предишно отваряне	5.31
Предишно затваряне	3.11

Настроения в новините

By Acuity

28%

72%

90 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.05.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on AI Enthusiasm -- Market Talk

11.05.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Rises on Possible Position Adjustments -- Market Talk

11.05.2026 г., 22:37 ч. UTC

Пазарно говорене

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11.05.2026 г., 22:32 ч. UTC

Печалби

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11.05.2026 г., 22:02 ч. UTC

Пазарно говорене

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11.05.2026 г., 21:49 ч. UTC

Печалби

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11.05.2026 г., 21:42 ч. UTC

Пазарно говорене

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11.05.2026 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

CSG Systems Sale to NEC Gets CFIUS Clearance

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv 1Q Loss/Shr $2.35 >OVV

11.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

11.05.2026 г., 20:44 ч. UTC

Печалби

Steris: Board Approves New $1B Shr Repurchase Program >STE

11.05.2026 г., 20:43 ч. UTC

Печалби

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Rev $136.4M >CLSK

11.05.2026 г., 20:30 ч. UTC

Печалби

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Cont Ops EPS $2.24 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Rev $1.6B >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Adj EPS $2.83 >STE

11.05.2026 г., 20:22 ч. UTC

Горещи акции

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11.05.2026 г., 19:37 ч. UTC

Печалби

More Bad News at KKR's Private Credit Fund -- Barrons.com

11.05.2026 г., 19:32 ч. UTC

Пазарно говорене

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

521.12% нагоре

12-месечна прогноза

Среден 20 USD 521.12%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

90 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.